Abstract | BACKGROUND: MATERIALS AND METHODS: RESULTS: Patients with weight loss>5% before chemotherapy had shorter progression-free survival period (5.8 months vs. 8.7 months; p=0.027) and overall survival (10.8 months vs. 20.0 months; p=0.010). Patients with weight loss>5% during chemotherapy tended to have shorter progression-free survival (6.0 months vs. 8.1 months; p=0.062) and overall survival (8.6 months vs. 18.0 months; p=0.022), and if weight loss was reversed during chemotherapy, survival rates improved. Furthermore, serum MIC-1 concentration was closely related to weight loss before chemotherapy (p=0.001) CONCLUSIONS: Weight loss both before and during chemotherapy predicted poor outcome in advanced ESCC patients, and MIC-1 might be involved in the development of weight loss in such patients.
|
Authors | Zhi-Hao Lu, Li Yang, Jing-Wei Yu, Ming Lu, Jian Li, Jun Zhou, Xi-Cheng Wang, Ji-Fang Gong, Jing Gao, Xiao-Tian Zhang, Jie Li, Yan Li, Lin Shen |
Journal | Asian Pacific journal of cancer prevention : APJCP
(Asian Pac J Cancer Prev)
Vol. 15
Issue 15
Pg. 6047-52
( 2014)
ISSN: 2476-762X [Electronic] Thailand |
PMID | 25124572
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Biomarkers, Tumor
- GDF15 protein, human
- Growth Differentiation Factor 15
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Biomarkers, Tumor
(blood)
- Carcinoma, Squamous Cell
(blood, drug therapy, mortality, secondary)
- Case-Control Studies
- Cohort Studies
- Esophageal Neoplasms
(blood, drug therapy, mortality, pathology)
- Female
- Follow-Up Studies
- Growth Differentiation Factor 15
(blood)
- Humans
- Lymphatic Metastasis
- Male
- Middle Aged
- Neoplasm Staging
- Prognosis
- Survival Rate
- Weight Loss
- Young Adult
|